GEN Exclusives

More »

GEN News Highlights

More »
Mar 30, 2007

Bavarian Nordic Obtains License to Vivalis’ ESC-derived Cell Lines

  • Vivalis granted Bavarian Nordic rights to evaluate the embryonic stem cell derived EBx® cells as a production platform of MVA-BN®-based (modified vaccinia Ankara-strain) vaccines.

    “We firmly believe that Vivalis’ chicken and duck EBx cell lines could be an attractive alternative to chicken embryonic fibroblasts for the industrial production of MVA-based vaccines,” says Franck Grimaud, CEO of Vivalis.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?